Haemonetics Corporation (HAE)
Haemonetics Corporation is a global medical technology company focused on blood and plasma component collection. They provide solutions for hospitals, blood centers, and plasma collection centers, aiming to improve patient outcomes and operational efficiency.
Company Overview
Haemonetics Corporation delivers innovative medical technology solutions for blood and plasma management, driving growth through its specialized offerings in blood component collection and hospital solutions, positioning itself as a key player in optimizing blood availability and patient care with a $2.78B market cap.
Investment Thesis
Haemonetics presents a compelling investment opportunity due to its leading position in the blood and plasma component collection market. The increasing demand for plasma-derived therapies and the growing need for efficient blood management in hospitals are key drivers for Haemonetics' growth. The company's innovative products, such as its automated plasma collection systems and transfusion management solutions, provide a competitive advantage. The company's established relationships with blood centers, plasma collection centers, and hospitals create a strong foundation for future growth. The company's market cap is $2.78B. Continued expansion into emerging markets and strategic acquisitions could further accelerate growth. Investors should consider Haemonetics for its potential to deliver long-term value through its specialized offerings and strong market position.
Key Highlights
- Haemonetics operates in the growing market of blood and plasma component collection.
- The company's Plasma segment benefits from the increasing demand for plasma-derived therapies.
- Haemonetics' Hospital segment offers solutions for blood transfusion management, hemostasis management, and cell salvage.
- The company has a global presence with operations in North America, Europe, Asia-Pacific, and Latin America.
- Haemonetics invests in research and development to expand its product portfolio and address unmet needs in blood management and patient care.
Competitors
Strengths
- Leading position in blood and plasma component collection.
- Innovative products and technologies.
- Global presence with operations in key markets.
- Strong relationships with blood centers, plasma collection centers, and hospitals.
Weaknesses
- Dependence on blood and plasma market trends.
- Exposure to regulatory changes and compliance requirements.
- Competition from other medical technology companies.
- Potential for product recalls or safety concerns.
Catalysts
- Upcoming: New product launches in automated plasma collection systems.
- Ongoing: Increasing demand for plasma-derived therapies.
- Ongoing: Expansion into emerging markets.
- Ongoing: Strategic partnerships with plasma collection centers and hospitals.
Risks
- Potential: Regulatory changes that could affect product approvals and market access.
- Potential: Economic downturns that could reduce healthcare spending.
- Ongoing: Competition from other medical technology companies.
- Potential: Product recalls or safety concerns.
Growth Opportunities
- Expansion in Emerging Markets: Haemonetics has a significant opportunity to expand its presence in emerging markets, where the demand for blood and plasma products is growing rapidly. These regions often lack advanced blood management infrastructure, presenting a significant opportunity for Haemonetics to introduce its technologies and solutions. By establishing partnerships with local healthcare providers and investing in infrastructure development, Haemonetics can tap into this underserved market and drive revenue growth.
- Strategic Acquisitions: Haemonetics can pursue strategic acquisitions to expand its product portfolio and geographic reach. Acquiring companies with complementary technologies or market access can accelerate Haemonetics' growth and strengthen its competitive position. These acquisitions can provide access to new markets, technologies, and customer segments, creating synergies and enhancing shareholder value.
- Development of New Products and Services: Haemonetics can invest in research and development to develop new products and services that address unmet needs in blood management and patient care. This includes developing more advanced automated plasma collection systems, transfusion management solutions, and hemostasis management technologies. By staying at the forefront of innovation, Haemonetics can maintain its competitive edge and capture new market opportunities.
- Increased Adoption of Automated Solutions: The increasing adoption of automated solutions in blood centers and hospitals presents a significant growth opportunity for Haemonetics. Automated systems can improve efficiency, reduce errors, and enhance the quality of blood products. By promoting the benefits of its automated solutions and providing comprehensive training and support, Haemonetics can drive adoption and increase its market share.
- Partnerships with Plasma Collection Centers: Haemonetics can strengthen its partnerships with plasma collection centers to increase the demand for its plasma collection systems and related services. By offering customized solutions, providing technical support, and collaborating on research and development, Haemonetics can become a preferred supplier to plasma collection centers and drive revenue growth. These partnerships can also provide valuable insights into market trends and customer needs, helping Haemonetics to develop more effective products and services.
Opportunities
- Expansion in emerging markets.
- Strategic acquisitions to expand product portfolio and geographic reach.
- Development of new products and services.
- Increased adoption of automated solutions.
Threats
- Economic downturns that could reduce healthcare spending.
- Technological disruptions that could render existing products obsolete.
- Increased competition from new entrants.
- Changes in reimbursement policies that could affect profitability.
Competitive Advantages
- Specialized Technology: Proprietary technology in blood and plasma component collection.
- Established Relationships: Long-standing relationships with blood centers, plasma collection centers, and hospitals.
- Regulatory Expertise: Deep understanding of regulatory requirements for blood and plasma products.
- Global Presence: Broad geographic reach with operations in key markets.
About
Haemonetics Corporation was founded in 1971 with a vision to improve blood management and patient outcomes. Over the decades, the company has evolved from a pioneer in blood processing technology to a global leader in blood and plasma component collection, transfusion management, and hemostasis management solutions. Haemonetics operates through three main segments: Plasma, Blood Center, and Hospital. The Plasma segment focuses on automated plasma collection technologies, software, and services, catering to the increasing demand for plasma-derived therapies. The Blood Center segment provides solutions for blood collection, processing, and storage, ensuring the availability of safe and effective blood products. The Hospital segment offers solutions for blood transfusion management, hemostasis management, and cell salvage, helping hospitals optimize blood utilization and improve patient care. Haemonetics' geographic reach spans North America, Europe, Asia-Pacific, and Latin America, with a strong presence in key markets. The company competes with other medical technology companies, focusing on innovation, customer service, and strategic partnerships to maintain its competitive edge. Haemonetics continues to invest in research and development to expand its product portfolio and address unmet needs in blood management and patient care.
What They Do
- Develop and manufacture automated blood component collection systems.
- Provide solutions for plasma collection, processing, and storage.
- Offer blood transfusion management solutions for hospitals.
- Develop hemostasis management technologies.
- Provide cell salvage solutions for surgical procedures.
- Offer software and services related to blood management.
Business Model
- Sales of automated blood component and plasma collection systems.
- Recurring revenue from consumables and service contracts.
- Sales of blood transfusion management and hemostasis management solutions.
- Revenue from software and related services.
FAQ
What does HAE do?
Haemonetics Corporation is a global medical technology company that provides a range of products and services for blood and plasma component collection, transfusion management, and hemostasis management. The company operates through three main segments: Plasma, Blood Center, and Hospital. Haemonetics' solutions are used by blood centers, plasma collection centers, and hospitals to improve efficiency, reduce errors, and enhance the quality of blood products. The company's products include automated plasma collection systems, blood transfusion management solutions, and hemostasis management technologies. Haemonetics aims to optimize blood availability and patient care.
Is HAE stock a good buy?
Haemonetics presents a compelling investment opportunity due to its leading position in the blood and plasma component collection market. The increasing demand for plasma-derived therapies and the growing need for efficient blood management in hospitals are key drivers for Haemonetics' growth. The company's innovative products, such as its automated plasma collection systems and transfusion management solutions, provide a competitive advantage. The company's established relationships with blood centers, plasma collection centers, and hospitals create a strong foundation for future growth. Investors should consider Haemonetics for its potential to deliver long-term value through its specialized offerings and strong market position. The company has a market cap of $2.78B.
What are the main risks for HAE?
Haemonetics faces several risks, including regulatory changes that could affect product approvals and market access. Economic downturns could reduce healthcare spending, impacting demand for the company's products and services. Competition from other medical technology companies could erode market share and profitability. Product recalls or safety concerns could damage the company's reputation and financial performance. Additionally, technological disruptions could render existing products obsolete, requiring significant investments in research and development to stay competitive. These risks should be carefully considered before investing in Haemonetics.
Industry Context
Haemonetics operates within the medical devices industry, specifically focusing on blood and plasma component collection and management. The industry is characterized by technological advancements, increasing regulatory scrutiny, and growing demand for efficient and safe blood management solutions. The market for blood and plasma products is driven by the rising prevalence of chronic diseases, the aging population, and the increasing use of plasma-derived therapies. Haemonetics competes with other medical technology companies that offer similar products and services. The company's focus on innovation, customer service, and strategic partnerships helps it maintain its competitive edge in this dynamic industry.
Key Customers
- Blood centers
- Plasma collection centers
- Hospitals
- Transfusion centers
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $339M | $45M | $0.00 |
| Q3 2025 | $327M | $39M | $0.00 |
| Q2 2025 | $321M | $34M | $0.00 |
| Q1 2025 | $331M | $58M | $0.00 |
Source: Company filings
Chart & Info
Price Chart
Haemonetics Corporation (HAE) stock price: $82.11 (+2.13, +2.66%)
Why Bull
- •Recent insider buying suggests confidence in Haemonetics' growth potential, indicating that leadership sees positive long-term prospects.
- •Community sentiment has shifted positively, with discussions highlighting the company's innovative blood management solutions and their increasing market demand.
- •Investors are optimistic about Haemonetics' expansion into new markets, particularly in emerging economies where healthcare infrastructure is improving.
- •Positive feedback from recent earnings calls indicates strong operational performance, reinforcing the belief that the company is on a solid growth trajectory.
Why Bear
- •Concerns have arisen regarding supply chain disruptions, which could hinder Haemonetics' ability to meet growing demand effectively.
- •Some community members express skepticism about the sustainability of recent revenue growth, fearing it may not be reflective of long-term trends.
- •Recent regulatory scrutiny in the healthcare sector has raised questions about potential operational challenges for Haemonetics moving forward.
- •Market perception remains cautious due to broader economic uncertainties, which could impact healthcare spending and, consequently, Haemonetics' performance.
Latest News
-
Haemonetics Q3 Earnings & Revenues Beat, Margins Up, Stock Slips
Zacks · Feb 6, 2026
-
Earnings Scheduled For February 5, 2026
benzinga · Feb 5, 2026
-
Datadog, Fastly, Planet Fitness, Air Products And Other Big Stocks Moving Higher On Thursday
benzinga · Nov 6, 2025
-
Earnings Scheduled For November 6, 2025
benzinga · Nov 6, 2025
Technical Analysis
Rationale
AI-generated technical analysis for HAE including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Haemonetics Corporation (HAE) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for HAE.
Make a Prediction
Set your price target for Haemonetics Corporation (HAE), choose a timeframe, and track your prediction accuracy.
Current price: $82.11
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HAE.
Price Targets
Wall Street price target analysis for HAE.
Insider Flow (30d)
No insider trades in the last 30 days.
MoonshotScore
Score Factors
- Revenue Growth 4/100
- Gross Margin 10/100
- Operating Leverage 4/100
- Cash Runway 5/100
- R&D Intensity 5/100
- Insider Activity 6/100
- Short Interest 5/100
- Price Momentum 0/100
- News Sentiment 5/100
What does this score mean?
The MoonshotScore rates HAE's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
Haemonetics Q3 Earnings & Revenues Beat, Margins Up, Stock Slips
Earnings Scheduled For February 5, 2026
Datadog, Fastly, Planet Fitness, Air Products And Other Big Stocks Moving Higher On Thursday
Earnings Scheduled For November 6, 2025
Frequently Asked Questions
What does HAE do?
Haemonetics Corporation is a global medical technology company that provides a range of products and services for blood and plasma component collection, transfusion management, and hemostasis management. The company operates through three main segments: Plasma, Blood Center, and Hospital. Haemonetics' solutions are used by blood centers, plasma collection centers, and hospitals to improve efficiency, reduce errors, and enhance the quality of blood products. The company's products include automated plasma collection systems, blood transfusion management solutions, and hemostasis management technologies. Haemonetics aims to optimize blood availability and patient care.
Is HAE stock a good buy?
Haemonetics presents a compelling investment opportunity due to its leading position in the blood and plasma component collection market. The increasing demand for plasma-derived therapies and the growing need for efficient blood management in hospitals are key drivers for Haemonetics' growth. The company's innovative products, such as its automated plasma collection systems and transfusion management solutions, provide a competitive advantage. The company's established relationships with blood centers, plasma collection centers, and hospitals create a strong foundation for future growth. Investors should consider Haemonetics for its potential to deliver long-term value through its specialized offerings and strong market position. The company has a market cap of $2.78B.
What are the main risks for HAE?
Haemonetics faces several risks, including regulatory changes that could affect product approvals and market access. Economic downturns could reduce healthcare spending, impacting demand for the company's products and services. Competition from other medical technology companies could erode market share and profitability. Product recalls or safety concerns could damage the company's reputation and financial performance. Additionally, technological disruptions could render existing products obsolete, requiring significant investments in research and development to stay competitive. These risks should be carefully considered before investing in Haemonetics.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.